Vascular endothelial growth factor, lipoporotein-associated phospholipase A2, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erithematosus

European Journal of Medical Research

Volumn 12, Issue 4, 2007, Pages 145-151

  Tanaseanu, C ^a   Tudor, S ^a   Tamsulea, I ^a   Marta, D ^b   Manea, G ^b   Moldoveanu, Elena ^b  

^a Sf Pantelimon Clin Emergency Hosp   (Romania)

^b NATIONAL INSTITUTE FOR RESEARCH AND DEVELOPMENT IN MICROTECHNOLOGIES   (Romania)

Author keywords

Antiphospholipid antibodies; Chronic pulmonary obstructive disease; Lipoporotein associated phospholipase A2; Pulmonary arterial hypertension; sP selectin; Systemic lupus erithematosus; Vascular endothelial growth factor

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1; BIOLOGICAL MARKER; CARDIOLIPIN ANTIBODY; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA ANTIBODY; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LUPUS ANTICOAGULANT; OXYGEN; PHOSPHOLIPASE A2; PHOSPHOLIPID ANTIBODY; PREDNISONE; RO ANTIBODY; SELECTIN; SM ANTIBODY; SP SELECTIN PROTEIN; THEOPHYLLINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PROGNOSIS; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGED; ANTIBODIES, ANTIPHOSPHOLIPID; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; P-SELECTIN; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34248520614     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2005 Jun; 43: 13S-24S.
2. Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004 Jun; 43: 5S-12S. Review.
3. Voelkel NF, Cool CD, Pulmonary vascular involvement in chronic obstructive pulmonary disease. Eur Respir J Suppl. 2003 Nov; 46:28s-32s.
4. Hass C. Pulmonary hypertension associated with systemic lupus erythematosus, Bull Acad Natl Med. 2004;188(6):985-97
5. Ninio E, Phospholipid mediators in the vessel wall: involvement in atherosclerosis. Curr Opin Clin Nutr Metab Care. 2005 Mar; 8(2):123-31. Review.
6. Tanaseanu C, Moldoveanu E, Kosaka T, Tanaseanu S, Neagu M, Popescu LM. The significance of human platelet-activating factor-acetylhydrolase in patients with chronic stable angina. Eur J Intern Med. 2004 Aug; 15(5):291-297.
7. Moldoveanu E, Tanaseanu C, Tanaseanu S, Kosaka T, Manea G, Marta DS, Popescu LM. Plasma markers of endothelial dysfunction in type 2 diabetics. Eur J Intern Med. 2006 Jan; 17(1):38-42.
8. Ferroni P, Basili S, Martini F, Vieri M, Labbadia G, Cordova C, Alessandri C, Gazzaniga PP. Soluble P-selectin as a marker of platelet hyperactivity in patients with chronic obstructive pulmonary disease. J Investig Med. 2000 Jan; 48(1): 21-7.
9. Joseph JE, Harrison P, Mackie IJ, Isenberg DA, Machin SJ. Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol. 2001 Nov; 115(2):451-9.
10. Blank M, Shoenfeld Y. Beta-2-glycoprotein-I, infections, antiphospholipid syndrome and therapeutic considerations. Clin Immunol. 2004 Aug; 112(2):190-9. Review.
11. Blank M, Asherson RA, Cervera R, Shoenfeld Y. Antiphospholipid syndrome infectious origin. J Clin Immunol. 2004 Jan; 24(1):12-23. Review.
12. Nishimura T, Vaszar LT, Faul JI, Zhao G, Berry GJ, Shi L, Qin D, Benson G, Pearl RG, Kao PN. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation. 2003 Sep 30; 108(13):1640-5.
13. British cardiac society Guidelines and medical practice Comitte, and approved by the British Thoracic Society and the British society of Rheumatology Recommendations on management of pulmonary hypertension in clinical practice Heart 2001; 86(suppl 1): 1-14.
14. Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, Olschewsky H, Peacock A, Pietra G, Rubin LJ, Simonneau G, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, McGregor K, Morais J, Oto A, Smiseth OA, Barbera JA, Gibbs S, Hoeper M, Humbert M, Naeije R, Pepke-Zaba J, Task Force. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004 Dec; 25(24):2243-78.
15. Agusti AGN. COPD a multicomponent disease: implications for management. Respir. Med. 2005 June; 99(6): 670-682.
16. Graninger W. Therapy of pulmonary involvement of rheumatic diseases. Z Rheumatol. 2003 Feb; 62(1):10-5. Review.
17. Gonzalez-Lopez L, Cardona-Munoz EG, Celis A, Garcia-de la Torre I, Orozco-Barocio G, Salazar-Paramo M, Garcia-Gonzalez C, Garcia-Gonzalez A, Sanchez-Ortiz A, Trujillo-Hernandez B, Gamez-Nava JI. Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus. Lupus. 2004; 13(2):105-12.
18. Lopes AA. Pathophysiological basis for anticoagulant and antithrombotic therapy in pulmonary hypertension. Cardiovasc Hematol Agents Med Chem. 2006 Jan; 4(1):53-9.
19. Reilly JJ, Silverman EK, Shapiro SD. Chronic obstructive pulmonary disease, 1547-1554 in Harrison's Principles of Internal Medicine 16th. Edition 2005. Editors: Kasper DL, Lony PL, Fonci AS, Braunwold E, Hansen SL, Jameson JL. The McGraro- Hill Companies Medical Publishing Division.
20. GOLD - Global initiative for chronic obstructive lung disease: global strategy for diagnosis management and prevention of COPD. Amer Respir Crit Care Med. 2001; 163:12564-76.
21. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004 Jun 16; 43(12 Suppl S):40S-47S. Review.
22. Mahmud E, Raisinghani A, Hassankhani A, Sadeghi HM, Strachan GM, Auger W, DeMaria AN, Blanchard DG. Correlation of left ventricular diastolic filling characteristics with right ventricular overload and pulmonary artery pressure in chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol. 2002 Jul 17; 40(2):318-24.
23. Torbicki A, Kurzyna M, Ciurzynski M, Pruszczyk P, Pacho R, Kuch-Wocial A, Szulc M. Proximal pulmonary emboli modify right ventricular ejection pattern. Eur Respir J. 1999 Mar; 13(3):616-21.
24. Kosaka T, Yamaguchi M, Soda Y, Kishimoto T, Tago A, Toyosato M, Mizuno K. Spectrophotometric assay for serum platelet-activating factor acetylhydrolase activity. Clin Chim Acta. 2000 Jun; 296(1-2):151-61.
25. Meroni PL, Borghi MO, Raschi E, Ventura D, Sarzi Puttini PC, Atzeni F, Lonati L, Parati G, Tincani A, Mari D, Tedesco F. Inflammatory response and the endothelium. Thromb Res. 2004; 114(5-6):329-34. Review.
26. Sakao S, Tatsumi K, Hashimoto T, Igari H, Shino Y, Shirasawa H, Kuriyama T. Vascular endothelial growth factor and the risk of smoking-related COPD. Chest. 2003 Jul; 124(1):323-7.
27. Tuder RM, Zhen L, Cho CY, Taraseviciene-Stewart L, Kasahara Y, Salvemini D, Voelkel NF, Flores SC. Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am J Respir Cell Mol Biol. 2003 Jul; 29(1):88-97.
28. Santos S, Peinado VI, Ramírez J, Morales-Blanhir J, Bastos R, Roca J, Rodriguez-Roisin R, Barberà JA. Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003 May 1; 167(9):1250-6.
29. Bigatello LM. Nitric oxide: modulation of the pulmonary circulation. Minerva anestesiol. 2000 May; 66(5):307-13.
30. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J. 2003 Aug, 22(2):358-63. Review.
31. Rose F, Hattar K, Gakisch S, Grimminger F, Olschewski H, Seeger W, Tschuschner A, Schermnly RT, Weissman N, Hanze j, Sibelius U, Ghofrani HA. Increased neutrophil mediator release in patients with pulmonary hypertension - suppression by inhaled iloprost. Thromb Haemost. 2003 Dec; 90(6):1141-9.
32. Kranenburg AR, de Boer WI, Alagappan VK, Sterk PJ, Sharma HS. Enhanced bronchial expression of vascular endothelial growth factor and receptors (Flk-1 and Fit-1) in patients with chronic obstructive pulmonary disease. Thorax. 2005 Feb; 60(2):106-13.
33. Kanazawa H, Yoshikawa J. Elevated oxidative stress and reciprocal reduction of vascular endothelial growth factor levels with severity of COPD. Chest. 2005 Nov; 128(5):3191-7.
34. Sakamaki F, Kyotani S, Nagaya N, Sato N, Oya H, Satoh T, Nakanishi N. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy. Circulation. 2001 Feb 6; 103(5):779.
35. Lopess AA. Pathophysiological basis for anticoagulant and antithrombotic therapy in pulmonary hypertension. Cardiovasc Hematol Agents Med Chem. 2006 Jan; 4(1):53-9.
36. Martini F, Riondino S, Basili S, Bertazzoni G, Ferroni P. In vivo platelet activation is associated with increased plasma levels of vascular endothelial growth factor. J Thromb Haemost. 2003 Apr; 1(4):853-4.
37. Rollin S, Lemieux C, Maliba R, Favier J, Villeneuve LR, Allen BG, Soker S, Bazan NG, Merhi Y, Sirois MG. VEGF-mediated endothelial P-selectin translocation: role of VEGF receptors and endogenous PAF synthesis. Blood. 2004 May 15; 103(10):3789-97. Epub 2004 Feb 5.
38. Pereira J, Alfaro G, Goycoolea M, Quiroga T, Ocqueteau M, Massardo L, Perez C, Saez C, Panes O, Matus V, Mezzano D. Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state. Thromb Haemost. 2006 Jan; 95(1):94-9.
39. Nagahama M, Nomura S, Ozaki Y, Yoshimura C, Kagawa H, Fukuhara S. Platelet activation markers and soluble adhesion molecules in patients with systemic lupus erythematosus. Autoimmunity. 2001; 33(2):85-94.
40. Romano SJ. Selectin antagonists: therapeutic potential in asthma and COPD. Treat Respir Med. 2005; 4(2):85-94. Review.
41. Schumacher A, Liebers U, John M, Gerl V, Meyer M, Witt C, Wolff G. P-selectin glycoprotein ligand-1 (PSGL-1) is up-regulated on leucocytes from patients with chronic obstructive pulmonary disease. Clin Exp Immunol. 2005 Nov; 142(2):370-6.
42. Ekdahl KN, Bengtsson AA, Andersson J, Elgue G, Ronnblom L, Sturfelt G, Nilsson B. Thrombotic disease in systemic lupus erythematosus is associated with a maintained systemic platelet activation. Br J Haematol. 2004 Apr; 125(1):74-8.
43. Joseph JE, Harrison P, Mackie IJ, Isenberg DA, Machin SJ. Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol. 2001 Nov; 115(2):451-9.
44. Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res. 2001 Feb 2; 88(2):245-50.
45. Pierangeli SS, Harris EN. Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells. Lupus. 2003; 12(7):539-45. Review.
46. Godeau B, Piette JC. The significance and treatment of antiphospholipid antibodies. Presse Med. 2004 Aug 28; 33(14 Pt 1):944-52. Review.